Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30164340 | 1.00 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL14861843 | 0.98 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL29610387 | 0.98 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3HTR6HTR1A | |
| Oxalic Acid SCHEMBL9595538 | 0.91 | SLC6A2 (0.52) | SLC6A4SLC6A2SLC6A3HTR1A | |
| Trifluoroacetic Acid SCHEMBL21590609 | 0.87 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23830675 | 0.86 | SLC6A2 (0.59) | SLC6A4SLC6A2SLC6A3HTR1AHTR2C | |
| SCHEMBL232364 | 0.86 | SLC6A2 (0.59) | SLC6A4SLC6A2SLC6A3HTR1AHTR2C | |
| SCHEMBL9923477 | 0.86 | SLC6A2 (0.59) | SLC6A4SLC6A2SLC6A3HTR1AHTR2C | |
| SCHEMBL23745914 | 0.84 | CHRNB2 (0.57) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL30422913 | 0.84 | CHRNB2 (0.57) | SLC6A4SLC6A2SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| CN-116783180-A | Tricyclic ligands for degradation of IKZF2 or IKZF4 | C4医药公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-4228639-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-9993477-B2 | Substituted imidazo[1,5-a]pyrazines as PDE9 inhibitors | H. LUNDBECK A/S (DK) | 2018-06-12 | — | — | US | disclosed |
| US-20170173018-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS PDE9 INHIBITORS | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1228065-A1 | (INDOL-3-YL)-CYCLOALKYL]-3-SUBSTITUTED AZETIDINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Wyeth (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6245799-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS; ANXIOLYTIC AGENTS | AMERICAN HOME PRODUCTS CORP | 2001-06-12 | — | — | US | disclosed |
| WO-2001034598-A1 | [(INDOL-3-YL)-CYCLOALKYL]-3-SUBSTITUTED AZETIDINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WYETH (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0131435-B1 | PROCESS FOR PREPARING 3-PHENOXY-1-AZETIDINES AND CARBOXAMIDE DERIVATIVES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1987-10-07 | — | — | EP | disclosed |
| EP-0102740-B1 | N-FORMYL AND N-HYDROXYMETHYL-3-PHENOXY-1-AZETIDINECARBOXAMIDES AND THEIR PREPARATION AND USE | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-11-05 | — | — | EP | disclosed |
| EP-0102194-B1 | 3-PHENOXY-1-AZETIDINECARBOXAMIDES AND THEIR USE AND PREPARATION | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4594189-A | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A. H. ROBINS COMPANY, INC. (US) | 1986-06-10 | — | — | US | disclosed |
| EP-0131435-A1 | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | SLC6A4 4312/4885SLC6A2 4822/4885SLC6A3 4776/4885 |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | SLC6A4 640/4885SLC6A2 411/4885SLC6A3 122/4885 |
| US-20170173018-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS PDE9 INHIBITORS | PDE9A, PDE12, PDE5A | SLC6A4 1190/4885SLC6A2 766/4885SLC6A3 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.